JavaScript isn't enabled in your browser, so this file can't be opened. Enable and reload.
3. Phase Ia_Ib trial of zongertinib (BI 1810631), a HER2-specific tyrosine kinase inhibitor (TKI), in patients (pts) with HER2 aberration-positive solid tumors Updated Phase Ia data from Beamion LUNG-1, including progressio
Slideshow
Share
Sign in
The version of the browser you are using is no longer supported. Please upgrade to a
supported browser
.
Dismiss
File
Edit
View
Help
Accessibility
Debug
Unsaved changes to Drive
Accessibility
View only
Rec
HTML view of the presentation